Transcatheter aortic valve replacement is a minimally invasive procedure used to treat aortic stenosis, a serious valve condition in which blood flow to the heart is restricted by a narrowing of the aortic valve opening. The procedure replaces the aortic valve without open-heart surgery.
The American College of Cardiology issued the certification after a nine-month evaluation that analyzed key areas at Mount Sinai Heart, including clinical outcomes, patient experience and infection control guidelines.
Earlier this year, U.S. News & World Report issued a “high performing” rating for Mount Sinai’s TAVR, among other procedures.
More articles on cardiology:
Duke surgeons perform 1,500th heart transplant
Devicemaker payments may influence cardiologists’ implant choice, study finds
5 pediatric heart practices cardiologists should question
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.